Analyst Price Target is $24.00
▲ +172.11% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Lumos Pharma in the last 3 months. The average price target is $24.00, with a high forecast of $28.00 and a low forecast of $20.00. The average price target represents a 172.11% upside from the last price of $8.82.
Current Consensus is
The current consensus among 3 investment analysts is to buy stock in Lumos Pharma. This Buy consensus rating has held steady for over two years.
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.